News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Archemix Corporation Initiates Phase 2a for Lead Aptamer Product Candidate ARC1779


3/30/2009 8:47:03 AM

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Archemix Corp., a privately-held biotechnology company working to develop aptamer-based therapeutics, announced today that it has initiated a Phase 2a clinical trial of its novel anti-von Willebrand Factor (VWF) aptamer, ARC1779. The trial is designed to evaluate the safety and efficacy of ARC1779 as a potential first-in-class anti-platelet agent in patients with carotid artery disease undergoing a surgical procedure known as carotid endarterectomy, or CEA.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES